Expression of L1CAM, COX-2, EGFR, c-KIT and Her2/neu in anaplastic pancreatic cancer: Putative therapeutic targets?

Histopathology

Volumn 56, Issue 4, 2010, Pages 440-448

  Bergmann, Frank ^a   Moldenhauer, Gerhard ^b   Herpel, Esther ^a   Gaida, Matthias M ^a   Strobel, Oliver ^a   Werner, Jens ^a   Esposito, Irene ^a   Müerköster, Susanne Sebens ^c   Schirmacher, Peter ^a   Kern, Michael A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Anaplastic carcinoma; Chemotherapy; Pancreatic cancer; Targeted therapy

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NERVE CELL ADHESION MOLECULE L1; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GIANT CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OSTEOCLAST; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; AGED; CYCLOOXYGENASE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURAL CELL ADHESION MOLECULE L1; PANCREATIC NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES;

EID: 77949639777     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03499.x     Document Type: Article

References (70)

1. Bergmann F, Esposito I, Michalski CW et al. Early undifferentiated pancreatic carcinoma with osteoclastlike giant cells: direct evidence for ductal evolution. Am. J. Surg. Pathol. 2007 31 1919 1925.
2. Klöppel G, Hruban RH, Longnecker DS, Adler G, Kern SE, Partanen TJ. Ductal adenocarcinoma of the pancreas. In Hamilton SR, Aaltonen LA eds. World Health Organisation classification of tumour. Pathology and genetics of tumours of the digestive system. Lyon : IARC Press, 2000 221 230.
3. Hoorens A, Prenzel K, Lemoine NR et al. Undifferentiated carcinoma of the pancreas: analysis of intermediate filament profile and Ki-ras mutations provides evidence of a ductal origin. J. Pathol. 1998 185 53 60.
4. Paal E, Thompson LD, Frommelt RA, Przygodki RM, Heffess CS. A clinicopathologic and immunohistochemical study of 35 anaplastic carcinomas of the pancreas with a review of the literature. Ann. Diagn. Pathol. 2001 5 129 140.
5. Molberg KH, Heffess C, Delgado R, Albores-Saavedra J. Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas and periampullary region. Cancer 1998 82 1279 1287.
6. Hruban RH, Bishop Pitman M, Klimstra DS. Tumors of the pancreas. In Silverberg SG, Sobin LH eds. Atlas of tumor pathology, 4rd Series, Fascicle. Washington, DC : Armed Forces Institute of Pathology, 2007 177 181.
7. Benedix F, Schmidt C, Schulz HU, Lippert H, Meyer F, Pech M. Continuous intra-arterial chemotherapy with 5-fluorouracil and cisplatin for locally advanced anaplastic carcinoma of the pancreas. Int. J. Colorectal Dis. 2008 23 729 731.
8. Bergmann F, Ceyhan GO, Rieker RJ et al. Fundamental differences in the neural invasion behavior of pancreatic endocrine tumors: relevance for local recurrence rates? Hum. Pathol. 2009 40 50 57.
9. Huszar M, Moldenhauer G, Gschwend V, Ben-Arie A, Altevogt P, Fogel M. Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Hum. Pathol. 2006 37 1000 1008.
10. Sebens Muerkoster S, Werbing V, Sipos B et al. Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene 2007 26 2759 2768.
11. Gast D, Riedle S, Schabath H et al. L1 augments cell migration and tumor growth but not beta3 integrin expression in ovarian carcinomas. Int. J. Cancer 2005 115 658 665.
12. Gavert N, Conacci-Sorrell M, Gast D et al. L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J. Cell Biol. 2005 168 633 642.
13. Boo YJ, Park JM, Kim J et al. L1 expression as a marker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer. Ann. Surg. Oncol. 2007 14 1703 1711.
14. Kaifi JT, Strelow A, Schurr PG et al. L1 (CD171) is highly expressed in gastrointestinal stromal tumors. Mod. Pathol. 2006 19 399 406.
15. Kaifi JT, Zinnkann U, Yekebas EF et al. L1 is a potential marker for poorly-differentiated pancreatic neuroendocrine carcinoma. World J. Gastroenterol. 2006 12 94 98.
16. Fogel M, Mechtersheimer S, Huszar M et al. L1 adhesion molecule (CD 171) in development and progression of human malignant melanoma. Cancer Lett. 2003 189 237 247.
17. Issa Y, Nummer D, Seibel T et al. Enhanced L1CAM expression on pancreatic tumor endothelium mediates selective tumor cell transmigration. J. Mol. Med. 2009 87 99 112.
18. Gast D, Riedle S, Issa Y et al. The cytoplasmic part of L1CAM controls growth and gene expression in human tumors that is reversed by therapeutic antibodies. Oncogene 2008 27 1281 1289.
19. Arlt MJ, Novak-Hofer I, Gast D et al. Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. Cancer Res. 2006 66 936 943.
20. Novak-Hofer I, Cohrs S, Grünberg J et al. Antibodies directed against L1CAM synergize with Genistein in inhibiting growth and survival pathways in SKOV3ip human ovarian cancer cells. Cancer Lett. 2008 261 193 204.
21. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol. Ther. 1999 82 241 250.
22. Barton CM, Hall PA, Hughes CM, Gullick WJ, Lemoine NR. Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J. Pathol. 1991 163 111 116.
23. Dong M, Nio Y, Guo KJ, Tamura K, Tian YL, Dong YT. Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. Anticancer Res. 1998 18 4613 4619.
24. Papouchado B, Erickson LA, Rohlinger AL et al. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod. Pathol. 2005 18 1329 1335.
25. Uegaki K, Nio Y, Inoue Y et al. Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. Anticancer Res. 1997 17 3841 3847.
26. Jardines L, Weiss M, Fowble B, Greene M. neu(c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer. Pathobiology 1993 61 268 282.
27. Derynck R, Goeddel DV, Ullrich A et al. Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res. 1987 47 707 712.
28. Ueda S, Hatsuse K, Tsuda H et al. Potential crosstalk between insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer. Mod. Pathol. 2006 19 788 796.
29. Pryczynicz A, Guzińska-Ustymowicz K, Kemona A, Czyzewska J. Expression of EGF and EGFR strongly correlates with metastasis of pancreatic ductal carcinoma. Anticancer Res. 2008 28 1399 1404.
30. Lemoine NR, Hughes CM, Barton CM et al. The epidermal growth factor receptor in human pancreatic cancer. J. Pathol. 1992 166 7 12.
31. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 1999 59 4356 4362.
32. Cho BC, Im CK, Park MS et al. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J. Clin. Oncol. 2007 25 2528 2533.
33. Feld R, Sridhar SS, Shepherd FA et al. Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review. J. Thorac. Oncol. 2006 1 367 376.
34. Siu LL, Soulieres D, Chen EX et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J. Clin. Oncol. 2007 25 2178 2183.
35. Zampino MG, Magni E, Massacesi C et al. First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. Cancer 2007 110 752 758.
36. Souglakos J, Kalykaki A, Vamvakas L et al. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Ann. Oncol. 2007 18 305 310.
37. Bergmann F, Breinig M, Höpfner M et al. Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors? Am. J. Gastroenterol. 2009 104 171 181.
38. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007 25 1960 1966.
39. Philip PA. Targeted therapies for pancreatic cancer. Gastrointest. Cancer Res. 2008 2 S16 S19.
40. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, Du Bois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994 107 1183 1188.
41. Bae SH, Jung ES, Park YM et al. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin. Cancer Res. 2001 7 1410 1418.
42. Wülfing P, Diallo R, Müller C et al. Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. J. Cancer Res. Clin. Oncol. 2003 129 375 382.
43. Hida T, Yatabe Y, Achiwa H et al. Increased expression of cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 1998 58 3761 3764.
44. Yang F, Bleich D. Transcriptional regulation of cyclooxygenase-2 gene in pancreatic beta-cells. J. Biol. Chem. 2004 279 35403 35411.
45. Sorli CH, Zhang HJ, Armstrong MB, Rajotte RV, Maclouf J, Robertson RP. Basal expression of cyclooxygenase-2 and nuclear factor-interleukin 6 are dominant and coordinately regulated by interleukin 1 in the pancreatic islet. Proc. Natl Acad. Sci. USA 1998 95 1788 1793.
46. Albazaz R, Verbeke CS, Rahman SH, McMahon MJ. Cyclooxygenase-2 expression associated with severity of PanIN lesions: a possible link between chronic pancreatitis and pancreatic cancer. Pancreatology 2005 5 361 369.
47. Kokawa A, Kondo H, Gotoda T et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 2001 91 333 338.
48. Kern MA, Schubert D, Sahi D et al. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 2002 36 885 894.
49. Rich TA, Shepard R. COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas. Am. J. Clin. Oncol. 2003 26 S110 S113.
50. Bertagnolli MM, Eagle CJ, Zauber AG et al. Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 2006 355 873 884.
51. Arber N, Eagle CJ, Spicak J et al. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 2006 355 885 895.
52. Half E, Sun Y, Sinicrope FA. Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells. Cancer Lett. 2007 251 237 246.
53. Reckamp KL, Krysan K, Morrow JD et al. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin. Cancer Res. 2006 12 3381 3388.
54. Kern MA, Haugg AM, Koch AF et al. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res. 2006 66 7059 7066.
55. Kern MA, Schoneweiss MM, Sahi D et al. Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. Carcinogenesis 2004 25 1193 1199.
56. Lanza-Jacoby S, Burd R, Rosato FE Jr. et al. Effect of simultaneous inhibition of epidermal growth factor receptor and cyclooxygenase-2 in HER-2/neu-positive breast cancer. Clin. Cancer Res. 2006 12 6161 6169.
57. Ali S, El-Rayes BF, Sarkar FH, Philip PA. Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Mol. Cancer Ther. 2005 4 1943 1951.
58. Esposito I, Kleeff J, Bischoff SC et al. The stem cell factor-c-kit system and mast cells in human pancreatic cancer. Lab. Invest. 2002 82 1481 1492.
59. Potti A, Ganti AK, Tendulkar K et al. HER-2/neu and CD117 (C-kit) overexpression in hepatocellular and pancreatic carcinoma. Anticancer Res. 2003 23 2671 2674.
60. Nio Y, Omori H, Toga T et al. Immunohistochemical expression of receptor-tyrosine kinase c-kit protein in invasive ductal carcinoma of the pancreas. Anticancer Drugs 2003 14 313 319.
61. Bateman AC, Judd M, Radenkovic D, Johnson CD. CD117/KIT expression in pancreatic adenocarcinoma. Pancreas 2008 36 76 79.
62. Heinrich MC, Corless CL, Demetri GD et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 2003 21 4342 4349.
63. Went PT, Dirnhofer S, Bundi M et al. Prevalence of KIT expression in human tumors. J. Clin. Oncol. 2004 22 4514 4522.
64. Cao D, Antonescu C, Wong G et al. Positive immunohistochemical staining of KIT in solid-pseudopapillary neoplasms of the pancreas is not associated with KIT/PDGFRA mutations. Mod. Pathol. 2006 19 1157 1163.
65. Yamanaka Y, Friess H, Kobrin MS et al. Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum. Pathol. 1993 24 1127 1134.
66. Safran H, Steinhoff M, Mangray S et al. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am. J. Clin. Oncol. 2001 24 496 499.
67. Saxby AJ, Nielsen A, Scarlett CJ et al. Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival. Am. J. Surg. Pathol. 2005 29 1125 1134.
68. Larbouret C, Robert B, Navarro-Teulon I et al. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin. Cancer Res. 2007 13 3356 3362.
69. Büchler P, Reber HA, Eibl G et al. Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy. Int. J. Oncol. 2005 27 1125 1130.
70. Saeki H, Yanoma S, Takemiya S et al. Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer. Oncol. Rep. 2007 18 433 439.